Nesina (nes-SEE-na, alogliptin) will compete in a crowded market of gliptins, or DPP-4 inhibitors, for type 2 diabetes

Nesina (nes-SEE-na, alogliptin) will compete in a crowded market of gliptins, or DPP-4 inhibitors, for type 2 diabetes.

It's a "me too"...similar to Januvia (sitagliptin), Onglyza (saxagliptin), and Tradjenta (linagliptin).

Continue to recommend lifestyle changes and metformin first.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter includes:

  • 12 issues every year, with brief articles about new meds and hot topics
  • 300+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get a quote